For virologically suppressed individuals 12 years or older weighing at least 35 kg with HIV-1. See Full Indication.
Clinical Trials for CABENUVA
CABENUVA has been studied extensively in two robust, Phase 3, clinical trials: ATLAS and FLAIR. The findings from these studies for once-monthly CABENUVA laid the foundation for ATLAS-2M, a large, Phase 3b noninferiority study comparing once-monthly CABENUVA to every-2-month CABENUVA. Click on the respective links below to view the data.
Once-Monthly CABENUVA Clinical Trials
See the results of 2 Phase 3 clinical trials, ATLAS and FLAIR, that evaluated once-monthly, long-acting CABENUVA vs continuing daily oral ARV therapy
Every-2-Month CABENUVA Clinical Trial
View data from ATLAS-2M, a Phase 3b clinical trial comparing once-monthly CABENUVA to every-2-month CABENUVA